PODD Earnings

PODD reported its FY2025Q4 earnings on 2026-02-18, showcasing a revenue of 0.00 against an estimate of 768.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 1.48 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following PODD's FY2025Q4 earnings announcement on 2026-02-18, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, PODD's stock price tends to shift by an average of +0.51% in the 10 days leading up to earnings and +0.59% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate PODD’s annual revenue to reach 768.00M, while the EPS is projected at 1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 2.52% and EPS estimates Revise Upward by 5.38% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between PODD's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 2.52%, while EPS estimates moved Revise Upward by 5.38% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PODD's stock price typically moves by +0.51% in the 10 days before its earnings and +0.59% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 1.00 and revenue of 768.00M.

The earnings call indicates strong financial performance with raised guidance for revenue and operating margins, driven by Omnipod's robust market presence and innovation. Despite management's avoidance of specific 2026 guidance, the positive growth trajectory, especially in international markets, and increased adoption in Type 2 diabetes, suggest a positive outlook. The Q&A supports this sentiment, highlighting strong science, brand equity, and strategic focus on market expansion. The absence of negative factors like margin declines or secondary offerings further supports a positive stock price movement prediction.